Rebekah Bordelon
Medical · Eunice, LANPI 1972906964
Payments from drug & device makers
Across 147 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$862
- GSK$490
- Novo Nordisk$101
- Astellas Pharma US Inc$95
- Dexcom, Inc.$89
- Pfizer$74
- plus $559 from 15 others
What the payments were for
- Food & beverage$2,17496%
- Education$954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $862 |
| GSK | 35 | $490 |
| Novo Nordisk | 7 | $101 |
| Astellas Pharma US Inc | 1 | $95 |
| Dexcom, Inc. | 5 | $89 |
| Pfizer | 5 | $74 |
| Novartis | 4 | $58 |
| Lilly USA, LLC | 4 | $57 |
| Ardelyx, Inc. | 3 | $56 |
| Exact Sciences | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Abbott | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| AstraZeneca | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Amgen | 2 | $25 |
| Boehringer Ingelheim | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $14 |
How this compares
$2,269 in reported general payments places this provider in the 70th percentile of 253 medical providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 88 | $107,640 |
| OzempicSemaglutide | 101 | $101,790 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $30,096 |
| LinzessLinaclotide | 17 | $15,785 |
| EntrestoSacubitril/Valsartan | 18 | $11,934 |
| XareltoRivaroxaban | 15 | $11,093 |
| JanuviaSitagliptin Phosphate | 11 | $8,137 |
| EliquisApixaban | 11 | $6,906 |
| MyrbetriqMirabegron | 11 | $5,082 |
| Varenicline Tartrate | 12 | $3,603 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $2,828 |
| Omeprazole | 124 | $1,357 |
| Diclofenac Sodium | 37 | $1,165 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,051 |
| Fluticasone Propionate | 81 | $831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $57 | $107,64088 claims |
| Novo NordiskOzempic | $101 | $101,790101 claims |
| GSKTrelegy Ellipta | $490 | $30,09644 claims |
| AbbVieLinzess | $862 | $15,78517 claims |
| NovartisEntresto | $58 | $11,93418 claims |
| PfizerEliquis | $74 | $6,90611 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $5,08211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 253 medical providers in Louisiana.
Other medical in Eunice
- Kristi RobertBaton Rouge$486K
- John Paul ThevenotMonroe$56K
- Vickie RiceBaton Rouge$19K
- Mary McFerrenShreveport$16K
- Rachel RhinehartJefferson$16K
- Sydney FussellCovington$16K
- Thomas BriscoeLafayette$13K
- Seth HendrixShreveport$12K
- Jessica PelusoNatchitoches$12K
- Heather RoanBossier City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.